Skip to main content

Table 3 Demographic data of patients following HTx

From: Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation

 

Control (n = 30)

Post-HTx (n = 85)

p-value*

No CAV (n = 62)

CAV (n = 23)

p-value†

Galectin-3 (ng/ml)

13.2 ± 9

17.8 ± 7

0.002

16.8 ± 6

20.5 ± 9

0.03

Age (yrs)

52 ± 8

55 ± 14

NS

54 ± 14

58 ± 13

NS

Gender (% male)

73 %

71 %

NS

80 %

81 %

0.02

BMI (kg/m2)

27 ± 5

29 ± 6

NS

29 ± 6

28 ± 5

NS

Etiology (%)

 Ischemic

-

32 %

-

54 %

45 %

NS

 Dilated

-

43 %

 

31 %

45 %

 

 Hypertrophy

-

2 %

 

0 %

3 %

 

 Unspecified

-

13 %

 

15 %

7 %

 

LVEF (%)

-

59 ± 8

 

60 ± 8

55 ± 8

<0.0001

Years post-HTx

-

5.4 ± 0.6

-

5.2 ± 1.2

5.5 ± 1.0

NS

Comorbidities

 Hypertension

13.3 %

61.7 %

<0.0001

55.6 %

67.7 %

NS

 Prior MIa

0 %

32.6 %

0.0003

25.9 %

45.2 %

NS

 Hyperlipidemia

23.3 %

48.3 %

0.02

50.0 %

45.2 %

NS

 Diabetes

0 %

49.4 %

<0.0001

50.0 %

41.9 %

NS

 Kidney Disease

0 %

38.2 %

<0.0001

31.5 %

48.4 %

NS

 COPDb

0 %

6.7 %

NS

7.4 %

3.2 %

NS

 Smoker

6.7 %

5.6 %

NS

7.4 %

3.2 %

NS

Lab Values

 WBCc (x103/μL)

7.6 ± 5

6.8 ± 2.3

NS

6.9 ± 2.2

6.6 ± 2.6

NS

 Nad (mEq/L)

145 ± 10

139 ± 2

<0.0001

139 ± 2

140 ± 2

NS

 Creae (mg/dL)

1.0 ± 0.3

1.5 ± 0.6

<0.0001

1.5 ± 0.5

1.7 ± 0.6

NS

 T-Bilig (mg/dL)

0.5 ± 0.2

0.7 ± 0.4

0.01

0.7 ± 0.3

0.8 ± 0.4

NS

 Albumin (g/dL)

4.9 ± 0.4

4.3 ± 0.4

<0.0001

4.3 ± 0.4

4.2 ± 0.5

0.05

  1. *p value versus controls; †p value versus no CAV
  2. aMI myocardial infarction, bCOPD chronic obstructive pulmonary disease, cWBC white blood count, eNa sodium, fCrea creatinine; gT-Bili total bilirubi006E